Adcetris, added to Pfizer’s portfolio with its Seagen acquisition in 2023, is indicated for multiple lymphoma conditions in the U.S. The company plans to discuss ECHELON-3 data with the FDA to ...

Seagen’s Adcetris was trounced by Bristol-Myers Squibb’s Opdivo in a head-to-head trial in classical Hodgkin lymphoma (cHL) reported at ASCO – but there may be a way for the drug to bounce back.

Adcetris has a list price of £2,500 per 50 mg vial – equivalent to almost £48,000 for the six treatment cycles required by the average patient – but has been recommended by NICE after Takeda ...